Recursion Pharmaceuticals, Inc. (RXRX) vs Shoulder Innovations, Inc. (SI)
A side-by-side comparison of Recursion Pharmaceuticals, Inc. and Shoulder Innovations, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
RXRX
Recursion Pharmaceuticals, Inc.
$4.08HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT
SI
Shoulder Innovations, Inc.
$19.17HealthcareDelayed quote: Oct 2, 2026, 3:39 PM EDT
Total return — RXRX vs SI
growth of $100 · dividends reinvested · last 1yRXRX -31.6% (-31.6%/yr)SI +24.6% (+24.6%/yr)SI compounded faster over this window
RXRX SI
RXRX vs SI: by the numbers
- •RXRX is the larger company ($2.14B vs $398M market cap).
- •Both run net losses; SI's is the smaller (-58.33% vs -945.92% net margin).
Metrics side by side
Valuation
| Metric | RXRX | SI |
|---|---|---|
| P/S ratio | 39.05 | 6.62 |
| P/B ratio | 2.34 | 3.20 |
Profitability
| Metric | RXRX | SI |
|---|---|---|
| Gross margin | -61.96% | 77.34% |
| Operating margin | -867.87% | -58.53% |
| Net margin | -945.92% | -58.33% |
| ROE | -56.71% | -28.18% |
| ROIC | -49.78% | -25.26% |
Growth (annualized)
| Metric | RXRX | SI |
|---|---|---|
| Revenue CAGR (5Y) | 45.50% | N/A |
| Total return CAGR (5Y) | -28.56% | N/A |
Go deeper
Dig into the metrics
Recursion Pharmaceuticals ROEShoulder Innovations ROERecursion Pharmaceuticals operating marginShoulder Innovations operating marginRecursion Pharmaceuticals revenue growthShoulder Innovations revenue growthRecursion Pharmaceuticals free cash flowShoulder Innovations free cash flow
Recursion Pharmaceuticals & Shoulder Innovations appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.